Data / Federal rules / 2026-10379

Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products

The Drug Enforcement Administration published this proposed rule in the Federal Register on May 26, 2026. Comments closed on June 25, 2026.

SpecStream is the live web data engine for teams and agents. It reads every rule and proposed rule in the Federal Register each morning, and this page is that reading. Name your industry once and new rules, comment deadlines and effective dates arrive in your sheet, CRM, Slack or agent as they are published.

Get new rules for your industry

What the agency says

The Drug Enforcement Administration (DEA) proposes to revoke the exempted status for certain nonnarcotic prescription products that are currently on DEA's Table of Exempted Prescription Products list but whose National Drug Code (NDC) is inactive because they are no longer available and/or the company that applied for the exemption no longer exists. If finalized, these products would be removed from DEA's Table of Exempted Prescription Products list, and they would no longer be considered exempt prescription products under the Controlled Substances Act. This action will not impact exempted prescription products with active NDC numbers.

Key facts

Document number: 2026-10379
Type: Proposed rule
Action: Notice of proposed rulemaking
Agency: Justice Department; Drug Enforcement Administration
Published: May 26, 2026
Comments due: June 25, 2026
Dates: Comments must be submitted electronically or postmarked on or before June 25, 2026.
Docket: Docket No. DEA-1664
Regulation ID (RIN): 1117-ZA08
Code of Federal Regulations: 21 CFR 1308
Pages: 6

The document on federalregister.gov PDF

Other documents from the Drug Enforcement Administration

Document	Type	Published
Schedules of Controlled Substances: Temporary Placement of 7- Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I 2026-20943	Proposed rule	Oct 14
Schedules of Controlled Substances: Temporary Placement of MGM-15 and MGM-16 in Schedule I 2026-20942	Proposed rule	Oct 14
Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products 2026-20757	Final rule	Oct 9
Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction 2026-20748	Final rule	Oct 9
Extension of Reexportation Period. 2026-20084	Proposed rule	Oct 1
Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I 2026-19400	Proposed rule	Sep 23
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I 2026-19231	Final rule	Sep 21
Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV 2026-17536	Final rule	Aug 27

Everything from the Drug Enforcement Administration · Published in May 2026

Read from the Federal Register API, last updated 2026-10-23. The document on federalregister.gov is the official record; dates and dockets can change through later corrections. Free to reuse with credit to SpecStream under CC BY 4.0.